Literature DB >> 7814549

Stabilities of quantitative plasma culture for human immunodeficiency virus, RNA, and p24 antigen from samples collected in VACUTAINER CPT and standard VACUTAINER tubes.

L Mole1, D Margolis, R Carroll, J Todd, M Holodniy.   

Abstract

We evaluated the stability of human immunodeficiency virus (HIV) load markers from blood samples collected in VACUTAINER CPT or standard VACUTAINER brand tubes using sodium heparin or sodium citrate as anticoagulants. Quantitative plasma culture and p24 antigen concentrations were determined, and HIV RNA levels in plasma were measured by both reverse transcription-PCR-enzyme-linked immunosorbent assay (RT-PCR-ELISA) and branched DNA methods. All tubes were stored at room temperature for analysis at 2, 24, 48, and 72 h after the blood samples were drawn. No difference was seen between tube types with respect to the HIV titer in plasma or the positivity rate for all samples that demonstrated a fall in titer over time. Unbound p24 antigen levels in plasma decreased during the initial 48-h period in both tube types. Immune complex-dissociated p24 antigen levels decreased in CPT tubes but not in standard VACUTAINER tubes. The HIV RNA copy number in plasma measured by RT-PCR-ELISA was stable in most subjects and was significantly higher in CPT tubes than in standard VACUTAINER tubes at 24 and 72 h after the blood samples were drawn. The branched DNA probe assay detected a significant decline in HIV RNA equivalent in plasma over 72 h in both collection tubes, the decline being more dramatic in the standard VACUTAINER tube than the CPT tube. Overall, interday variability suggests that samples collected for a particular assay should be processed at the same time after blood is drawn and that a particular tube type be used throughout a given study.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 7814549      PMCID: PMC263969          DOI: 10.1128/jcm.32.9.2212-2215.1994

Source DB:  PubMed          Journal:  J Clin Microbiol        ISSN: 0095-1137            Impact factor:   5.948


  10 in total

1.  Reduction in plasma human immunodeficiency virus ribonucleic acid after dideoxynucleoside therapy as determined by the polymerase chain reaction.

Authors:  M Holodniy; D A Katzenstein; D M Israelski; T C Merigan
Journal:  J Clin Invest       Date:  1991-11       Impact factor: 14.808

2.  Effect of platelet-associated virus on assays of HIV-1 in plasma.

Authors:  T H Lee; R R Stromberg; D Henrard; M P Busch
Journal:  Science       Date:  1993-12-03       Impact factor: 47.728

Review 3.  Use of virologic assays for detection of human immunodeficiency virus in clinical trials: recommendations of the AIDS Clinical Trials Group Virology Committee.

Authors:  S Hammer; C Crumpacker; R D'Aquila; B Jackson; J Lathey; D Livnat; P Reichelderfer
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

4.  Diurnal and short-term stability of HIV virus load as measured by gene amplification.

Authors:  M Holodniy; L Mole; M Winters; T C Merigan
Journal:  J Acquir Immune Defic Syndr (1988)       Date:  1994-04

5.  Quantitation of human immunodeficiency virus type 1 in the blood of infected persons.

Authors:  D D Ho; T Moudgil; M Alam
Journal:  N Engl J Med       Date:  1989-12-14       Impact factor: 91.245

6.  Quantitative evaluation of hepatitis C virus RNA in patients with concurrent human immunodeficiency virus infections.

Authors:  K E Sherman; J O'Brien; A G Gutierrez; S Harrison; M Urdea; P Neuwald; J Wilber
Journal:  J Clin Microbiol       Date:  1993-10       Impact factor: 5.948

7.  Infectious decay of human immunodeficiency virus type 1 in plasma.

Authors:  T Moudgil; E S Daar
Journal:  J Infect Dis       Date:  1993-01       Impact factor: 5.226

8.  Cell-free plasma human immunodeficiency virus type 1 titer assessed by culture and immunocapture-reverse transcription-polymerase chain reaction.

Authors:  R W Coombs; D R Henrard; W F Mehaffey; J Gibson; E Eggert; T C Quinn; J Phillips
Journal:  J Clin Microbiol       Date:  1993-08       Impact factor: 5.948

9.  Viricidal effect of polymorphonuclear leukocytes on human immunodeficiency virus-1. Role of the myeloperoxidase system.

Authors:  S J Klebanoff; R W Coombs
Journal:  J Clin Invest       Date:  1992-06       Impact factor: 14.808

10.  Loss of infectivity ex vivo in plasma of human immunodeficiency virus-infected patients correlates with a high CD4 cell count.

Authors:  P L Vernazza; J J Eron; S A Fiscus
Journal:  J Infect Dis       Date:  1993-11       Impact factor: 5.226

  10 in total
  8 in total

1.  Assessment of hepatitis B virus DNA stability in serum by the Chiron Quantiplex branched-DNA assay.

Authors:  M Krajden; L Comanor; O Rifkin; A Grigoriew; J M Minor; G F Kapke
Journal:  J Clin Microbiol       Date:  1998-02       Impact factor: 5.948

2.  TaqMan real-time reverse transcription-PCR and JDVp26 antigen capture enzyme-linked immunosorbent assay to quantify Jembrana disease virus load during the acute phase of in vivo infection.

Authors:  Meredith Stewart; Moira Desport; Nining Hartaningsih; Graham Wilcox
Journal:  J Clin Microbiol       Date:  2005-11       Impact factor: 5.948

3.  Effects of anticoagulant, processing delay, and assay method (branched DNA versus reverse transcriptase PCR) on measurement of human immunodeficiency virus type 1 RNA levels in plasma.

Authors:  L M Kirstein; J W Mellors; C R Rinaldo; J B Margolick; J V Giorgi; J P Phair; E Dietz; P Gupta; C H Sherlock; R Hogg; J S Montaner; A Muñoz
Journal:  J Clin Microbiol       Date:  1999-08       Impact factor: 5.948

4.  Effects of specimen collection, processing, and storage conditions on stability of human immunodeficiency virus type 1 RNA levels in plasma.

Authors:  C C Ginocchio; X P Wang; M H Kaplan; G Mulligan; D Witt; J W Romano; M Cronin; R Carroll
Journal:  J Clin Microbiol       Date:  1997-11       Impact factor: 5.948

5.  The effect of ex vivo CDDO-Me activation on nuclear factor erythroid 2-related factor 2 pathway in white blood cells from patients with septic shock.

Authors:  Sanjeev Noel; Laura Zheng; Ana Navas-Acien; Ralph J Fuchs
Journal:  Shock       Date:  2014-11       Impact factor: 3.454

6.  Comparative stabilities of quantitative human immunodeficiency virus RNA in plasma from samples collected in VACUTAINER CPT, VACUTAINER PPT, and standard VACUTAINER tubes.

Authors:  M Holodniy; L Mole; B Yen-Lieberman; D Margolis; C Starkey; R Carroll; T Spahlinger; J Todd; J B Jackson
Journal:  J Clin Microbiol       Date:  1995-06       Impact factor: 5.948

7.  Maternal plasma human immunodeficiency virus type 1 RNA level: a determinant and projected threshold for mother-to-child transmission.

Authors:  G Fang; H Burger; R Grimson; P Tropper; S Nachman; D Mayers; O Weislow; R Moore; C Reyelt; N Hutcheon; D Baker; B Weiser
Journal:  Proc Natl Acad Sci U S A       Date:  1995-12-19       Impact factor: 11.205

8.  Immune cell subsets and their gene expression profiles from human PBMC isolated by Vacutainer Cell Preparation Tube (CPT™) and standard density gradient.

Authors:  Christopher P Corkum; Danielle P Ings; Christopher Burgess; Sylwia Karwowska; Werner Kroll; Tomasz I Michalak
Journal:  BMC Immunol       Date:  2015-08-26       Impact factor: 3.615

  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.